Intracellular Drug Accumulation | List of Frontiers open access articles

Original Research

Published on 31 Oct 2014

Reduced Intracellular Drug Accumulation in Drug-Resistant Leukemia Cells is Not Only Solely Due to MDR-Mediated Efflux but also to Decreased Uptake

in Cancer Molecular Targets and Therapeutics

Angela Oliveira Pisco
Dean Andrew Jackson
Sui Huang

Frontiers in Oncology

doi 10.3389/fonc.2014.00306

8,380 views
26 citations

Original Research

Published on 09 Feb 2016

Molecular Characterization of Gβ-Like Protein CpcB Involved in Antifungal Drug Susceptibility and Virulence in A. fumigatus

in Fungi and Their Interactions

Zhendong Cai
Yanfei Chai
Caiyun Zhang
Ruoyun Feng
Hong Sang
Ling Lu

Frontiers in Microbiology

doi 10.3389/fmicb.2016.00106

4,110 views
12 citations

Original Research

Published on 17 Jan 2022

Anlotinib Reverses Multidrug Resistance (MDR) in Osteosarcoma by Inhibiting P-Glycoprotein (PGP1) Function In Vitro and In Vivo

in Pharmacology of Anti-Cancer Drugs

Gangyang Wang
Lingling Cao
Yafei Jiang
Tao Zhang
Hongsheng Wang
Zhuoying Wang
Jing Xu
Min Mao
Yingqi Hua
Zhengdong Cai

Frontiers in Pharmacology

doi 10.3389/fphar.2021.798837

4,102 views
20 citations

Brief Research Report

Published on 25 Apr 2022

Phenethylisothiocyanate Potentiates Platinum Therapy by Reversing Cisplatin Resistance in Cervical Cancer

in Pharmacology of Anti-Cancer Drugs

Elizabeth Mahapatra
Debomita Sengupta
Ravindra Kumar
Budheswar Dehury
Salini Das
Madhumita Roy
Sutapa Mukherjee

Frontiers in Pharmacology

doi 10.3389/fphar.2022.803114

4,376 views
12 citations

Original Research

Published on 19 Jul 2021

Branebrutinib (BMS-986195), a Bruton’s Tyrosine Kinase Inhibitor, Resensitizes P-Glycoprotein-Overexpressing Multidrug-Resistant Cancer Cells to Chemotherapeutic Agents

in Molecular and Cellular Oncology

Chung-Pu Wu
Megumi Murakami
Yu-Shan Wu
Ya-Chen Chi
Sung-Han Hsiao
Yang-Hui Huang
Tai-Ho Hung
Suresh V. Ambudkar

Frontiers in Cell and Developmental Biology

doi 10.3389/fcell.2021.699571

4,575 views
9 citations

Original Research

Published on 16 Apr 2019

Novel 3,4-Dihydroisocoumarins Inhibit Human P-gp and BCRP in Multidrug Resistant Tumors and Demonstrate Substrate Inhibition of Yeast Pdr5

in Cancer Molecular Targets and Therapeutics

Julia Sachs
Katja Döhl
Anja Weber
Michele Bonus
Ferdinand Ehlers
Edmond Fleischer
Anette Klinger
Holger Gohlke
Jörg Pietruszka
Lutz Schmitt

Frontiers in Pharmacology

doi 10.3389/fphar.2019.00400

6,260 views
17 citations

Original Research

Published on 09 Oct 2018

Olmutinib (BI1482694/HM61713), a Novel Epidermal Growth Factor Receptor Tyrosine Kinase Inhibitor, Reverses ABCG2-Mediated Multidrug Resistance in Cancer Cells

in Experimental Pharmacology and Drug Discovery

Wei Zhang
Ying-Fang Fan
Chao-Yun Cai
Jing-Quan Wang
Qiu-Xu Teng
Zi-Ning Lei
Leli Zeng
Pranav Gupta
Zhe-Sheng Chen

Frontiers in Pharmacology

doi 10.3389/fphar.2018.01097

5,613 views
56 citations

Articles

Reduced Intracellular Drug Accumulation in Drug-Resistant Leukemia Cells is Not Only Solely Due to MDR-Mediated Efflux but also to Decreased Uptake

Molecular Characterization of Gβ-Like Protein CpcB Involved in Antifungal Drug Susceptibility and Virulence in A. fumigatus

Anlotinib Reverses Multidrug Resistance (MDR) in Osteosarcoma by Inhibiting P-Glycoprotein (PGP1) Function In Vitro and In Vivo

Phenethylisothiocyanate Potentiates Platinum Therapy by Reversing Cisplatin Resistance in Cervical Cancer

Branebrutinib (BMS-986195), a Bruton’s Tyrosine Kinase Inhibitor, Resensitizes P-Glycoprotein-Overexpressing Multidrug-Resistant Cancer Cells to Chemotherapeutic Agents

Novel 3,4-Dihydroisocoumarins Inhibit Human P-gp and BCRP in Multidrug Resistant Tumors and Demonstrate Substrate Inhibition of Yeast Pdr5

Olmutinib (BI1482694/HM61713), a Novel Epidermal Growth Factor Receptor Tyrosine Kinase Inhibitor, Reverses ABCG2-Mediated Multidrug Resistance in Cancer Cells